semaglutide vs sglt2 Effects of with and without concomitant inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial Addition of Ozempic to a
Description
Marc Ronert told The Post.
Alo breaks down the SELECT trial data, debunks the "muscle melting" myth with new NIH research, and shares his protocol for protecting lean mass.
David Shafer explains why volume loss appears, what helps, and when fillers may work.
Listen now (38 mins) | Low cost medications with total transparency was just the beginning
Robust GIP Affinity: Optimized to drive complex lipid buffering and cellular homeostasis studies
